Mergers and acquisitions (M&A) in the pharma and biotech sector have accelerated notably year to date, building on a rebound in 2025. A recent surge in dealmaking underscores the industry’s focus on portfolio expansion and continuous pipeline innovation, alongside a growing emphasis on AI-driven drug discovery. Oncology and immuno-oncology companies have always been at the top of acquisition targets. Major players are actively pursuing licensing agreements and collaborations around promising drugs and candidates to further strengthen and diversify their core portfolios.
Read the full article: Pharma, Biotech Giants Ramp Up M&A in Q1 to Boost Pipelines //
Source: https://finance.yahoo.com/sectors/healthcare/articles/pharma-biotech-giants-ramp-m-190600040.html